Navigation Links
Cardium to Present at 10th Annual Biotech in Europe Investor Forum
Date:9/20/2010

ets with coronary artery disease.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio.  News from Cardium is located at www.cardiumthx.com.

Copyright 2010 Cardium Therapeutics, Inc.  All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics™ Generx® and MedPodium™ are trademarks of Cardium Therapeutics, Inc.

Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™, Osteorate™, Appexium™ and Linee™ are trademarks of Tissue Repair Company.


'/>"/>
SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cardium Regains Listing Compliance With NYSE Amex
2. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
3. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
4. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
5. Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
6. Cardium Completes $6.0 Million Registered Direct Offering
7. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
8. Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
9. Cardium Regains Listing Compliance with NYSE Amex
10. Cardiums InnerCool Therapies Business to Be Acquired By Royal Philips Electronics
11. Cardium Announces Conference Call and Webcast to Review Recent Developments and Future Plans for the Excellarate(TM) Clinical Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... LA JOLLA, Calif. , July 30, 2014 /PRNewswire/ ... RGLS ), a biopharmaceutical company leading the discovery and ... it will report financial results and highlights for the ... 2014, after the U.S. financial markets close. ... on Wednesday, August 6, 2014, at 5:00 pm Eastern ...
(Date:7/30/2014)... and PARIS , July 30, 2014 ... SAN and NYSE: SNY) today announced that the Companies ... (FDA) rare pediatric disease priority review voucher in connection ...  The priority review voucher entitles the holder to designate ... expedited 6-month review from the filing date instead of ...
(Date:7/30/2014)... 30, 2014 W. R. Grace ... of the REVELERIS® Prep purification system , ... chromatographers, and other researchers to perform both flash ... unit. , With the REVELERIS® Prep purification system, ... chromatography modes with a simple touch of the ...
(Date:7/30/2014)... 30, 2014  Decision Resources Group finds that ... in the United States ... penetration will be the level of savings achievable ... expected lower cost to patients. Payers plan to ... their pricing expectations in order to encourage physician ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Grace Launches New REVELERIS® Prep Purification System 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... Revenue Increased 61% Compared to 3Q06 to $43.5 Million in 3Q07 -,- 3Q07 ... ... Share - - Company Provides Financial ... Oriental,Bioengineering, Inc. (NYSE: AOB ), a leading manufacturer and distributor of,plant-based pharmaceutical ...
... ... up 10%, Compared to Third Quarter 2006 FFO Per Share (Diluted) of ... $1.32 - Third Quarter 2007 Total Revenues up 23%, FFO Available to ... Stockholders up 21% - Third Quarter 2007 Earnings Per Share (Diluted) ...
... Bruker Daltonics today,announced the availability of its ... poster presentations on its website at, http://www.bdal.com . ... Characterization and General Mass Spectrometry, -- Novel ... Peptide Characterization Poster M103 ...
Cached Biology Technology:American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 2American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 3American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 4American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 5American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 6American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 7American Oriental Bioengineering Reports Third Quarter 2007 Financial Results 8Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 2Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 3Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 4Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 5Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 6Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 7Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 8Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 9Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 10Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 11Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 12Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 13Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 14Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 15Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 16Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 17Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 18Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 19Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 20Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 21Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 22Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 23Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 24Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 25Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 26Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 27Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 28Alexandria Real Estate Equities, Inc. Reports Third Quarter 2007 Results 29
(Date:7/30/2014)... map of the carbon stocks stored on land ... and improved methodology used to make the map ... economies. The new carbon map also reveals ... the critical input to studies of deforestation and ... purposes. The technique includes the determination of uncertainty ...
(Date:7/29/2014)... and applications for imaging and manipulation of the brain ... the inspiration behind Neurophotonics , a new peer-reviewed ... and photonics. , The first issue coincides with the ... and a special section features articles that lay out ... that optics and photonics will have on advancing our ...
(Date:7/29/2014)... a restaurant, don,t blame yourself; blame the menu. What ... want and more to do with a menu,s layout and ... over 300 diners, the Cornell study published this month in ... when it comes to what you order for dinner, two ... how you imagine it will taste. , First, any food ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3SPIE launches Neurophotonics journal with special section on BRAIN Initiative 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 3Menu secrets that can make you slim by design 2
... University scientists are working to determine how neurons are ... disorders like Tuberous Sclerosis Complex (TSC). TSC is ... tumors in the brain and other vital organs and ... impairment that may arise from the abnormal generation of ...
... who invest in their own solar panels for the roof ... the long term but how long will this technology ... up to 25 years to their customers, the manufacturers themselves ... modules must fulfill certain standards, of course, to be approved ...
... fundamental processes in the life of plants because they have ... Leeds researchers. Arabidopsis thaliana also known as thale ... over Europe and Asia, but the small white flower leads ... world. It has become the dominant "model plant" in ...
Cached Biology News:Clemson University study points to possible treatment for brain disorders 2Predicting the life expectancy of solar modules 2Predicting the life expectancy of solar modules 3Model plant misled scientists about multicellular growth 2Model plant misled scientists about multicellular growth 3
HOXC11 Antibody...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Anti-MMP-19 (RASI), carboxy terminal region; rabbit host...
Rabbit polyclonal to ATF4 (phospho S245) ( Abpromise for all tested applications). Antigen: Synthetic phosphopeptide derived from human ATF4 around the phosphorylation site of Serine 245. En...
Biology Products: